Clinical Trials · NCT01360840
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- EMD Serono
- Enrollment
- 180
- Start date
- Apr 2011
- Locations
- 71 sites, 12 countries
- Primary endpoint
- Progression Free Survival (PFS) Time